氨基分子螢光標誌Cy5.5 NHS ester (non-sulfonated) | APExBIO 貨號A8103
| 代理廠牌： |  |
| 原廠連結： | |
| 相關下載： |
特點
雷帕黴菌（Rapamycin）| Romidepsin (FK228, depsipeptide) | Daptomycin | G-418 (80 S 核醣體延伸抑制劑)
氨基分子螢光標誌Cy5.5 NHS ester (non-sulfonated)| APExBIO 貨號A8103 Purity = 98.00%
Cyanine5.5 NHS 酯(Cy5.5-NHS ester)是一種活性染料，用於標記含有氨基的胜肽(peptides)、蛋白質(proteins)和寡核苷酸(oligonucleotides)。 Cy5.5-NHS 酯(Cy5.5-NHS ester)是一種近紅外線螢光染料(near-infrared fluorescence dye )，能夠溶解在 DMF 和 DMSO 中，激發最大值和發射最大值分別約為 675 nm 和 693 nm [1]。此試劑不僅可用於標記含有氨基的分子，還可用於標記質粒DNA(plasmid DNA) [2]。對於生物分子標記，標記試劑的水溶性較低，需要使用有機共溶劑溶解該分子才能有效進行反應。首先，將花青染料(Cyanine dye)溶解在有機溶劑中，然後加入適當的水性緩衝液中的生物分子溶液中。
透過皮下腫瘤異種移植小鼠(subcutaneous tumor xenografted mice)的光學成像(optical imaging)，注射0.5 nmol Cy5.5-NHS後30分鐘至24小時，皮下U87MG腫瘤可與周圍背景組織清楚地區分開。 Cy5.5-NHS 的腫瘤攝取在注射後 30 分鐘達到最大值，並隨著時間的推移慢慢被沖走 [3]。
Labeling of amino-groups in biomolecules.
- 1. Debin Zheng, Jingfei Liu, et al. “Enzyme-instructed and mitochondria-targeting peptide self-assembly to efficiently induce immunogenic cell death.” Acta Pharm Sin B. 2022 Jun;12(6):2740-2750. PMID: 35755291
- 2. Shaodan Ma, Shunan Gu, et al. “Robust drug bioavailability and safety for rheumatoid arthritis therapy using D-amino acids-based supramolecular hydrogels.” Mater Today Bio. 2022 May 19;15:100296. PMID: 35665233
- 3. Qi Wang , Ting Li, et al. “Engineered Exosomes with Independent Module/Cascading Function for Therapy of Parkinson’s Disease by Multistep Targeting and Multistage Intervention Method.” Adv Mater. 2022 Apr 18;e2201406. PMID: 35435282
- 4. Xiaoyun Li, Rui Wu, et al. “Near-Infrared Light-Driven Multifunctional Tubular Micromotors for Treatment of Atherosclerosis.” ACS Appl Mater Interfaces. 2021 Jul 7;13(26):30930-30940. PMID: 34156244
- 5. Zhanpeng Wen, Jie Zhan, et al. “Dual-ligand supramolecular nanofibers inspired by the renin-angiotensin system for the targeting and synergistic therapy of myocardial infarction.” Theranostics. 2021 Jan 27;11(8):3725-3741. PMID: 33664858
- 6. Qingle Ma, Qin Fan, et al. “Platelet-derived extracellula
APExBIO提供優質的胜肽和生物分析試劑，廣泛產品線如Protease、Chromatin/Epigenetics表觀遺傳學、MAPK Signal、DNA Damege/DNA repair、細胞凋亡、腫瘤生物學、Stem cell等研究領域， 還提供定制的服務，包括多肽合成，抗體的生產和檢測的發展。產品線DNA/RNA prep kit、Drug Screening panel、Bioactive peptides、Growth factors、Biotinylation Reagents、tag peptides、amino Acids、Growth factors等。APExBIO產品質量都伴隨著證書的分析，高效液相色譜，質譜，和HMNR數據。
| 品項 | CAS# | #貨號 | 應用 |
| Z-VAD-FMK | CAS# 187389-52-2 | 貨號 A1902 |
Proteases ICE-like proteases |
| TAPI-1 | CAS#171235-71-5 | 貨號 B4686 |
Proteases TACE/ADAM17 inhibitor Product Citation+3 |
| Talabostat mesylate | CAS# 150080-09-4 | 貨號B3941 |
Proteases DPP4 二肽基肽酶特異性抑制劑 |
| Z-IETD-FMK | CAS# 210344-98-2 | 貨號B3232 | inhibitor of caspase 8 |
| Cisplatin | CAS# 15663-27-1 | 貨號A8321 | 高效、廣譜的化療藥物 |
| 17-DMAG (Alvespimycin) HCl | CAS#467214-21-7 | 貨號A2213 | Hsp90 inhibitor |
| CA-074 Me | CAS# 147859-80-1 | 貨號A8239 | Cathepsin B inhibitor |
| VX-765 | CAS# 273404-37-8 | 貨號A8238 | Caspase-1 inhibitor |
| A8100 | Cy3 NHS ester (non-sulfonated) | 98.00% | Labeling of amino-groups in biomolecules. | |
| A8101 | Cy3.5 NHS ester (non-sulfonated) | 98.00% | Labeling of amino-groups in biomolecules. | |
| A8102 | Cy5 NHS ester (non-sulfonated) | 98.00% | Labeling of amino-groups in biomolecules. | |
| A8103 | Cy5.5 NHS ester (non-sulfonated) | 98.00% | Labeling of amino-groups in biomolecules. | |
| A8104 | Cy7 NHS ester (non-sulfonated) | 1432019-64-1 | 98.00% | Labeling of amino-groups in biomolecules. |
| A8105 | Cy7.5 NHS ester (non-sulfonated) | 95.88% | Labeling of amino-groups in biomolecules. | |
| A8107 | Cy3 NHS ester | 95.00% | Labeling of amino-groups in biomolecules. | |
| A8108 | Cy5 NHS ester | 98.00% | Labeling of amino-groups in biomolecules. | |
| A8109 | Cy7 NHS ester | 98.00% | Labeling of amino-groups in biomolecules. | |
| A8111 | Cy3 azide (non-sulfonated) | 99.44% | used for Click chemistry to label alkyne-modified oligonucleotides | |
| A8112 | Cy3.5 azide (non-sulfonated) | 96.24% | used for Click chemistry to label alkyne-modified oligonucleotides | |
| A8113 | Cy5 azide (non-sulfonated) | 99.54% | used for Click chemistry to label alkyne-modified oligonucleotides | |
| A8114 | Cy5.5 azide (non-sulfonated) | 97.94% | used for Click chemistry to label alkyne-modified oligonucleotides | |
| A8115 | Cy7 azide (non-sulfonated) | 98.00% | used for Click chemistry to label alkyne-modified oligonucleotides | |
| A8116 | Cy7.5 azide (non-sulfonated) | 98.00% | used for Click chemistry to label alkyne-modified oligonucleotides | |
| A8117 | FAM azide, 5- isomer | 98.00% | Fluorescent lablels | |
| A8123 | Pyrene azide 3 | 99.42% | Reagent for fluorescent labeling | |
| A8127 | Cy3 azide | 99.70% | used for Click chemistry to label alkyne-modified oligonucleotides | |
| A8128 | Cy5 azide | 98.00% | used for Click chemistry to label alkyne-modified oligonucleotides | |
| A8130 | Cy3 alkyne (non-sulfonated) | 98.53% | used for Click chemistry to label any molecule bearing azide group. | |
| A8131 | Cy5 alkyne (non-sulfonated) | 99.10% | used for Click chemistry to label any molecule bearing azide group. | |
| A8132 | Cy3 carboxylic acid (non-sulfonated) | 98.00% | Non-reactive fluorophore, for control experiments, and for calibration | |
| A8133 | Cy5 carboxylic acid (non-sulfonated) | 98.00% | Non-reactive fluorophore, for control experiments, and for calibration | |
| A8134 | Cy5.5 carboxylic acid (non-sulfonated) | 98.16% | Non-reactive fluorophore, for control experiments, and for calibration | |
| A8135 | Cy7 carboxylic acid (non-sulfonated) | 98.00% | Non-reactive fluorophore, for control experiments, and for calibration | |
| A8136 | Cy7.5 carboxylic acid (non-sulfonated) | 98.00% | Non-reactive fluorophore, for control experiments, and for calibration | |
| A8137 | Cy5 carboxylic acid | 98.00% | Non-reactive fluorophore, for control experiments, and for calibration | |
| A8138 | Cy3 maleimide (non-sulfonated) | 98.00% | Labeling of cysteine residues, as well as other thiolated molecules | |
| A8139 | Cy5 maleimide (non-sulfonated) | 98.00% | Labeling of cysteine residues, as well as other thiolated molecules | |
| A8140 | Cy5.5 maleimide (non-sulfonated) | 96.27% | Labeling of cysteine residues, as well as other thiolated molecules | |
| A8142 | Cy7.5 maleimide(non-sulfonated) | 99.01% | Labeling of cysteine residues, as well as other thiolated molecules | |
| A8143 | Cy5 amine (non-sulfonated) | 98.00% | can be conjugated with reactive groups such as NHS esters, carboxy groups (after carbodiimide activation), and epoxides. | |
| A8144 | Cy5 Boc-hydrazide (non-sulfonated) | 98.00% | carbonyl-reactive dye | |
| A8145 | Cy5 hydrazide (non-sulfonated) | 98.00% | carbonyl-reactive dye | |
| A8147 | Azidobutyric acid NHS ester | 98.00% | Azide-labeling to amino-containing biomolecules | |
| A8158 | Ascorbic acid | 89924-69-6 | 98.00% | antioxidant |
| A8162 | E-64-c | 76684-89-4 | 97.51% | Inhibitor of cysteine proteinases |
| A8163 | AM 114 | 856849-35-9 | 98.00% | 20S proteasome inhibitor |
| A8164 | Cyclo (-RGDfK) | 161552-03-0 | 98.00% | Inhibitor of αvβ3 integrin |
| A8165 | Q-VD(OMe)-OPh | 98.00% | Pan-caspase inhibitor | |
| A8167 | Rapamycin (Sirolimus) | 53123-88-9 | 98.00% | Original antifungal antibiotic |
| A8168 | HA14-1 | 65673-63-4 | 98.79% | Bcl-2 inhibitor,potent and cell-permeable |
| A8169 | Everolimus (RAD001) | 159351-69-6 | 98.46% | MTOR inhibitor |
| A8170 | Z-FA-FMK | 105637-38-5;197855-65-5 | 98.00% | Cysteine proteases inhibitor |
| A8171 | Entinostat (MS-275,SNDX-275) | 209783-80-2 | 99.04% | HDAC1 and HDAC3 inhibitor |
| A8172 | Dihydroeponemycin | 126463-64-7 | 90.72% | Proteasome inhibitor,antitumor reagent,eponemycin ddrivative |
| A8173 | Romidepsin (FK228, depsipeptide) | 128517-07-7 | 99.14% | HDAC1/HDAC2 inhibitor, potent and selective |
| A8174 | Cathepsin G Inhibitor I | 429676-93-7 | 95.56% | Cathepsin G inhibitor |
| A8176 | Apicidin | 183506-66-3 | ≥90.00% | Potent HDAC inhibitor |
| A8177 | PAC-1 | 315183-21-2 | 99.90% | Procaspase-3 activator |
| A8178 | Panobinostat (LBH589) | 404950-80-7 | 98.85% | HDAC inhibitor |
| A8179 | MG-262 | 179324-22-2 | 98.92% | Proteasome inhibitor |
| A8180 | KN-62 | 127191-97-3 | 99.32% | CaM kinase II inhibitor |
| A8181 | (-)-JQ1 | 1268524-71-5 | 99.06% | Stereoisomer of (+)-JQ1, used as negative control |
| A8182 | 3-Deazaneplanocin A (DZNep) hydrochloride | 120964-45-6 | 98.00% | SAHH and EZH2 inhibitor |
| A8183 | Trichostatin A (TSA) | 58880-19-6 | 98.22% | HDAC inhibitor |
| A8184 | AICAR | 2627-69-2 | 99.92% | AMPK activator |
| A8185 | SR 11302 | 160162-42-5 | ≥ 95.00% | AP-1 transcription factor inhibitor |
| A8187 | Guanosine-2′(3′)-monophosphate disodium salt | 6027-83-4 | 98.00% | A mixture of the 2′ and 3′-isomers of GMP |
| A8188 | Atractyloside Dipotassium Salt | 102130-43-8 | 98.00% | AAT inhibitor |
| A8189 | PSI-6206 | 863329-66-2 | 99.97% | Inhibitor of HCV RNA polymerase,potent and selective |
| A8190 | Semagacestat (LY450139) | 425386-60-3 | 99.40% | γ-secretase inhibitor |
| A8191 | Nanaomycin A | 52934-83-5 | 98.00% | DNMT3B inhibitor |
| A8192 | Staurosporine | 62996-74-1 | 99.91% | Protein kinase inhibitor,potent and cell permeable |
| A8193 | ABT-737 | 852808-04-9 | 97.61% | Bcl-2 inhibitor |
| A8194 | ABT-199 | 1257044-40-8 | 98.07% | Bcl-2 inhibitor,potent and selective |
| A8197 | Compound 56 | 171745-13-4 | 97.00% | REGFR inhibitor |
| A8198 | P 22077 | 1247819-59-5 | 98.00% | USP7/(DUB)USP47 inhibitor |
| A8199 | PD153035 hydrochloride | 153436-54-5 | 99.60% | Potent EGFR inhibitor |
| A8200 | DAPT (GSI-IX) | 208255-80-5 | 99.08% | γ-secretase inhibitor,potent and specific |
| A8201 | Amprenavir (agenerase) | 161814-49-9 | 99.31% | HIV-1 protease inhibitor |
| A8202 | Abiraterone acetate | 154229-18-2 | 99.72% | Cytochrome p450 17a1 inhibitor |
| A8203 | Ritonavir | 155213-67-5 | 99.57% | HIV protease inhibitor |
| A8204 | Lopinavir | 192725-17-0 | 99.80% | HIV protease inhibitor,highly potent |
| A8205 | Atazanavir | 198904-31-3 | 99.48% | HIV protease inhibitor,highly potent |
| A8206 | Darunavir | 206361-99-1 | 99.91% | HIV-1 protease inhibitor |
| A8207 | AZD6244 (Selumetinib) | 606143-52-6 | 98.45% | MEK inhibitor |
| A8208 | Tariquidar | 206873-63-4 | 98.79% | P-glycoprotein inhibitor,potent and non-competitive |
| A8210 | GDC-0941 | 957054-30-7 | 99.57% | PI3K inhibitor,potent and selective |
| A8212 | PR-619 | 2645-32-1 | 99.96% | Deubiquitylating enzymes (DBUs) inhibitor |
| A8213 | KY 02111 | 1118807-13-8 | 99.84% | WNT signaling inhibitor |
| A8214 | AZD8055 | 1009298-09-2 | 98.02% | MTOR inhibitor |
| A8215 | PP 1 | 172889-26-8 | 96.03% | Src family tyrosine kinase inhibitor |
| A8216 | PP 2 (AG 1879) | 172889-27-9 | 99.39% | Src-family kinases inhibitor |
| A8217 | ICG 001 | 847591-62-2 | 99.72% | Wnt/β-catenin pathway inhibitor |
| A8218 | Lapatinib | 231277-92-2 | 99.58% | EGFR/HER2 inhibitor,potent,selective and reversible |
| A8219 | Gefitinib (ZD1839) | 184475-35-2 | 99.89% | Selective EGFR inhibitor |
| A8221 | EPZ-6438 | 1403254-99-8 | 99.42% | EZH2 inhibitor, potent and selective |
| A8222 | BX795 | 702675-74-9 | 94.28% | PDK1 inhibitor |
| A8223 | CID 2011756 | 638156-11-3 | 97.79% | PKD inhibitor |
| A8224 | StemRegenin 1 (SR1) | 1227633-49-9 | 99.13% | AhR antagonist |
| A8225 | Ezatiostat | 168682-53-9 | 97.00% | (GST) P1-1 inhibitor |
| A8226 | TAK-632 | 1228591-30-7 | 99.01% | Pan-RAF inhibitor,potent and selective |
| A8228 | Purmorphamine | 483367-10-8 | 99.04% | Hedgehog agonist |
| A8229 | ML161 | 423735-93-7 | 97.00% | PAR1 inhibitor |
| A8232 | Nilotinib(AMN-107) | 641571-10-0 | 99.85% | Bcr-Abl kinase inhibitor,selective |
| A8233 | DMXAA (Vadimezan) | 117570-53-3 | 97.00% | Tumnor vascular disrupting agent, apoptosis inducer |
| A8234 | Erlotinib Hydrochloride | 183319-69-9 | 99.55% | Selective EGFR inhibitor |
| A8235 | Embelin | 550-24-3 | 98.10% | XIAP inhibitor,cell-permeable |
| A8236 | Regorafenib | 755037-03-7 | 99.46% | Inhibitor of VEGFR/PDGFR/FGFR/mutant kit/RET/Raf-1 |
| A8237 | SKLB610 | 1125780-41-7 | 99.43% | Potent VEGFR inhibitor |
| A8238 | VX-765 | 273404-37-8 | 99.57% | Caspase-1 inhibitor,potent and selective |
| A8239 | CA-074 Me | 147859-80-1 | 97.98% | Cathepsin B inhibitor |
| A8240 | SB 216763 | 280744-09-4 | 99.33% | GSK-3 inhibitor,ATP-competitive,potent and selective |
| A8241 | SB 415286 | 264218-23-7 | 98.93% | GSK-3 inhibitor,potent and selective |
| A8242 | Splitomicin | 5690-03-9 | 98.00% | inhibitor of Sir2p and fMLP-induced free radicals |
| A8244 | Cycloheximide | 66-81-9 | 99.63% | Antibiotic,inhibitor of protein synthesis in eukaryotes |
| A8245 | Sorafenib Tosylate | 475207-59-1 | 99.79% | Raf kinases and tyrosine kinases inhibitor |
| A8246 | BEZ235 (NVP-BEZ235) | 915019-65-7 | 97.71% | PI3K/mTOR inhibitor,ATP-competitve |
| A8247 | Afatinib (BIBW2992) | 439081-18-2 | 98.83% | Irreversible EGFR/HER2 inhibitor |
| A8248 | ZSTK474 | 475110-96-4 | 98.00% | Potent PI3K inhibitor |
| A8249 | SB 431542 | 301836-41-9 | 99.64% | ALK inhibitor |
| A8250 | LY 294002 | 154447-36-6 | 99.97% | Potent PI3K inhibitor |
| A8251 | TAE684 (NVP-TAE684) | 761439-42-3 | 99.00% | ALK inhibitor,potent and selective |
| A8252 | Nintedanib (BIBF 1120) | 656247-17-5 | 97.22% | VEGFR/PDGFR/FGFR inhibitor |
| A8253 | PD 173074 | 219580-11-7 | 98.21% | FGFR inhibitor |
| A8254 | SB 203580 | 152121-47-6 | 99.59% | P38 MAP kinase inhibitor |
| A8255 | Sunitinib malate | 341031-54-7 | 99.27% | VEGFR/PDGFRβ/ KIT/ FLT3/RET/CSF-1R inhibitor |
| A8260 | Cyanine3.5 carboxylic acid | 98.23% | Non-reactive reference dye or control | |
| A8261 | Cy5.5 hydrazide (non-sulfonated) | N/A | 98.00% | carbonyl-reactive dye |
| A8262 | Cy3.5 alkyne (non-sulfonated) | N/A | 98.99% | dye alkyne for click chemistry |
| A8263 | Cy5.5 alkyne (non-sulfonated) | 96.11% | Far red/near infrared dye for Click Chemistry labeling | |
| A8264 | Cy3.5 maleimide (non-sulfonated) | N/A | 98.00% | Labeling of cysteine residues, as well as other thiolated molecules |
| A8265 | Cy3 hydrazide (non-sulfonated) | 96.13% | carbonyl-reactive dye | |
| A8266 | Cy3.5 hydrazide (non-sulfonated) | N/A | 98.00% | carbonyl-reactive dye |
| A8267 | OAC2 | 6019-39-2 | 97.74% | Oct4 activator |
| A8268 | OAC3 | 182564-41-6 | 98.00% | Oct4 activator |
| A8300 | ZCL278 | 587841-73-4 | 97.00% | Selective Cdc42 inhibitor |